Shlomo Yanai - Perrigo Company Independent Director Nominee

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:3em;padding-top: 40px;;'>PRG</div>
PRGO -- USA Stock  

Last Earning Anouncement Date: December 31, 2015  

Mr. Shlomo Yanai is Independent Director Nominee of the Company. He served as Chief Executive Officer and as President of Teva Pharmaceutical Industries Ltd., a global pharmaceutical company, from March 2007 to May 2012. He was an independent director of Sagent Pharmaceuticals, Inc., since April 2015 a director of Quinpario Acquisition Corporationration 2 since November 2014 a director and NonExecutive Chairman of Cambrex since November 2012 and a director of Lumenis Ltd. since December 2012. He also serves as a member of an advisory board at Paragon Pharmaceuticals, LLC a member of the International Advisory Board of the MBA program of BenGurion University as well as an honorary member of the board of the Universitys Institute for Policy and Strategy of the Interdisciplinary Center. Mr. Yanai also served 32 years with the Israeli Defense forces, retiring in 2001 with the rank of Major General.
Age: 62        
353 1 709 4000  http://www.perrigo.com

Management Efficiency

The company has return on total asset (ROA) of 2.19 % which means that it generated profit of $2.19 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 4.32 % meaning that it created $4.32 on every $100 dollars invested by stockholders.
The company currently holds 3.5 B in liabilities with Debt to Equity (D/E) ratio of 60.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Perrigo Company has Current Ratio of 2.03 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Alan GarberVertex Pharmaceuticals Incorpor
Sanjay KhoslaZoetis
Geoffery MerszeiOrigin Agritech Limited
Willie ReedZoetis
Robert ScullyZoetis
Michael TrimbleOrigin Agritech Limited
Terrence KearneyVertex Pharmaceuticals Incorpor
Larry CordellOrigin Agritech Limited
Frank DAmelioZoetis
Huda ZoghbiRegeneron Pharmaceuticals
Marc TessierLavigneRegeneron Pharmaceuticals
Sridar IyengarDr Reddys Laboratories Ltd
Omkar GoswamiDr Reddys Laboratories Ltd
David AltshulerVertex Pharmaceuticals Incorpor
Bruce SachsVertex Pharmaceuticals Incorpor
Lloyd CarneyVertex Pharmaceuticals Incorpor
Yingqi XiaOrigin Agritech Limited
Bruce CarterDr Reddys Laboratories Ltd
Hans HaslerDr Reddys Laboratories Ltd
Arthur RyanRegeneron Pharmaceuticals
Linda RhodesZoetis

Company Summary

Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Perrigo Company operates under Drug ManufacturersSpecialty Generic classification in USA and is traded on BATS Exchange. It employs 10600 people.Perrigo Company Plc (PRGO) is traded on BATS Exchange in USA and employs 10,600 people.

Perrigo Company Leadership Team

John Hendrickson, PresidentView
Gary Cohen, Independent DirectorView
Arthur Shannon, IR Contact OfficerView
Ronald Winowiecki, Acting CFOView
Svend Andersen, Executive Vice President and President - Consumer Healthcare InternationalView
Judy Brown, CFO and Executive VPView
Laurie Brlas, Independent DirectorView
Donal OConnor, Independent DirectorView
James Michaud, Chief Human Resource Officer, Executive Vice PresidentView
Louis Yu, Executive Vice President - Global QualityView
John Wesolowski, Executive Vice President and Presidentident - RXView
Theodore Samuelsto, Independent DirectorView
Scott Jamison, Executive Vice President General Manager - NutritionalsView
Ellen Hoffing, Independent DirectorView
Marc Coucke, Executive Vice President General Manager - Omega Pharma BusinessView
Adriana Karaboutis, Independent DirectorView
Michael Jandernoa, Independent DirectorView
Paul Weninger, Executive Vice President - Global Quality OperationsView
Thomas Farrington, Senior Vice President CIOView
Herman Morris, Independent DirectorView
Jeffrey Needham, Executive Vice President General Manager - Consumer HealthcareView
Todd Kingma, Executive VP, General Counsel and SecretaryView
Rolf Classon, Independent DirectorView
Raymond Silcock, CFOView
Shlomo Yanai, Independent Director NomineeView
Jatin Shah, Senior Vice President Chief Scientific OfficerView
Michael Stewart, Senior Vice President - Global Human ResourcesView
Jeffrey Kindler, Independent DirectorView
Jacqualyn Fouse, Independent DirectorView
Grainne Quinn, Executive Vice President Chief Medical OfficerView
Theodore Samuels, Independent DirectorView
Geoffrey Parker, Independent DirectorView
Murray Kessler, President CEO, DirectorView
Sharon Kochan, Executive VP and General Manager of InternationalView
Gary Kunkle, Lead Independent DirectorView
Joseph Papa, Chairman and CEOView
Marry Brlas, Independent Chairman of the BoardView
Bradley Alford, Independent DirectorView
Jeffrey Smith, Independent DirectorView
Bradley Joseph, IR Contact OfficerView
James Dillard, Executive Vice President Chief Scientific OfficerView
Douglas Boothe, Executive Vice President General Manager - Rx PharmaceuticalsView
Ronald Janish, Executive Vice President - Global Operations and Supply ChainView
Uwe Rohrhoff, President CEO, DirectorView

Stock Performance Indicators

Did you try this?

Run Price Exposure Probability Now


Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased one share of
few hours ago
Traded for 116.67
Purchased few shares of
few hours ago
Traded for 58.5
Purchased few shares of
few hours ago
Traded for 66.38
Purchased few shares of
few hours ago
Traded for 150.13
Purchased few shares of
few hours ago
Traded for 48.82
Please check Your Equity Center. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.